2 Top Blue-Chip Stocks to Buy and Hold in 2026

Key Concepts

Blue Chip Stocks: Stocks of large, financially stable, industry-leading companies.
Economic Moat: A company’s ability to maintain competitive advantages over its rivals, protecting its long-term profits. Specifically, “wide economic moats” represent significant and durable advantages.
Market Capitalization: The total value of a company’s outstanding shares (stock price multiplied by the number of shares).
Compound Annual Growth Rate (CAGR): The average annual growth rate of an investment over a specified period, assuming profits are reinvested during the term.
Secular Growth Drivers: Long-term trends that are expected to fuel growth in a particular industry or company.
Pipeline (Pharmaceutical): The collection of potential drug candidates a pharmaceutical company is developing.
Patent Losses: The expiration of exclusive rights to manufacture and sell a drug, opening the market to generic competition.

Understanding Blue Chip Stocks & Identifying Undervalued Opportunities

The discussion centers on identifying undervalued blue chip stocks suitable for long-term investment, drawing from Morningstar’s “Best Companies to Own” list. Blue chip stocks are defined as those belonging to large, well-established, and financially sound companies that are leaders within their respective industries. These are generally considered less risky investments due to their inherent financial stability. The focus is on companies exhibiting “wide economic moats” – significant and sustainable competitive advantages. Specifically, the analysis targets stocks with market capitalizations exceeding $100 billion.

Microsoft: A Growth Opportunity Driven by Innovation

Microsoft is presented as the first undervalued blue chip stock. Morningstar has assigned it a “wide economic moat” rating based on three key factors: switching costs, network effects, and cost advantages.

Switching Costs: The difficulties and expenses associated with a customer changing to a competitor’s product or service. Microsoft’s integrated software ecosystem creates high switching costs.
Network Effects: The value of a product or service increases as more people use it. Microsoft’s platforms benefit from this, as wider adoption enhances their utility.
Cost Advantages: Microsoft’s scale and efficiency allow it to produce goods or services at a lower cost than competitors.

The company’s financial health is described as excellent, citing a strong balance sheet, growing revenue, and expanding margins. Microsoft is positioned to benefit from “secular growth drivers” like artificial intelligence (AI) and public cloud computing. Morningstar models a 5-year Compound Annual Growth Rate (CAGR) of approximately 13% for revenue. Currently, the stock is trading below its estimated fair value of $600 per share.

Bristol Myers Squibb: Navigating Patent Expirations with a Robust Pipeline

The second undervalued stock highlighted is Bristol Myers Squibb (BMS), a pharmaceutical company. BMS possesses a “wide economic moat” due to its strong drug portfolio and a robust development pipeline. The company is proactively addressing upcoming patent expirations on key drugs between now and 2028, which are anticipated to cause a 4% CAGR decline in sales over the next five years.

However, BMS is heavily investing in research and development, focusing on areas with significant unmet medical needs, including:

Immunology
Oncology
Rare Diseases
Cardiology
Neurology

This strategic shift aims to mitigate the impact of patent losses and establish a new generation of revenue-generating drugs. The analysis suggests the market is currently undervaluing BMS, with an estimated fair value of $66 per share.

Methodological Framework & Data Points

The analysis relies on Morningstar’s proprietary research and valuation methodologies, specifically their “Best Companies to Own” list which prioritizes companies with wide economic moats. Key data points include:

Market Capitalization Threshold: > $100 billion
Microsoft 5-Year Revenue CAGR: 13%
Bristol Myers Squibb 5-Year Sales CAGR (Projected Decline): -4%
Microsoft Fair Value Estimate: $600
Bristol Myers Squibb Fair Value Estimate: $66

Logical Connections & Argumentation

The presentation logically connects the concept of blue chip stocks with the importance of identifying companies possessing durable competitive advantages (economic moats). The selection criteria – undervaluation and large market capitalization – are presented as filters to identify potentially attractive investment opportunities. The arguments for both Microsoft and Bristol Myers Squibb are supported by specific details regarding their financial health, growth prospects, and strategic positioning.

Conclusion

The core takeaway is that both Microsoft and Bristol Myers Squibb represent undervalued blue chip stocks with strong fundamentals and long-term growth potential. Microsoft benefits from established market dominance and emerging technologies, while Bristol Myers Squibb is proactively addressing challenges and investing in future innovation. Investors are encouraged to consider these stocks for a buy-and-hold strategy and to consult Morningstar’s resources (Morning Filter podcast and morningstar.com) for further research. As Susan Jabinsky stated, “We think Microsoft stock is worth $600 and shares trade well below that,” and “We think the market is underestimating Bristol Myers Squib. We think shares are worth $66.”